Clinical trials: Epileptic Encephalopathy
Developmental and Epileptic Encephalopathy
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed…
- Trial name
- NCT06908226
- Testing
- LP352
- Where
- 88 sites in United States, Australia and 15 more
- Volunteers
- 324 people
- Sponsor
- Longboard Pharmaceuticals
Seizure, Epileptic
Pathophysiology Based Therapy of Early Onset Epileptic Encephalopathies
Genetic epileptic encephalopathies (EEs) are a group of very rare and severe, pharmaco-resistant epilepsy forms characterized by an early onset, e.g. first years of life, and an often severe developmental delay.
- Trial name
- EE (NCT02968966)
- Testing
- Therapy regime
- Where
- Germany
- Sponsor
- University Hospital Tuebingen
Dravet Syndrome, Lennox Gastaut Syndrome
Intermediate-Size Expanded Access Protocol (EAP) for LP352
This is an intermediate-size expanded access program (EAP) study. The purpose of this EAP is to provide continued access to LP352, an investigational drug product being investigated in participants with DEEs.
- Conditions
- Dravet Syndrome, Lennox Gastaut Syndrome, Developmental and Epileptic Encephalopathies
- Trial name
- NCT06149663
- Testing
- LP352
- Where
- 22 sites in United States, Australia
- Sponsor
- Longboard Pharmaceuticals
CSWS, Developmental and/or Epileptic Encephalopathies
Melatonin for the Treatment of DEE-SWAS
The goal of this study is to learn if melatonin, a naturally produced substance, can help to treat some of the symptoms of DEE-SWAS, a type of epilepsy that causes children to lose skills and development.
- Conditions
- CSWS, Developmental and/or Epileptic Encephalopathies, Electrical Status Epilepticus in Sleep
- Trial name
- NCT07221968
- Testing
- Melatonin
- Volunteers
- 3 people
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder, Developmental and Epileptic Encephalopathy
Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy
This study is to evaluate the use of glycerol phenylbutyrate for monogenetic developmental epileptic encephalopathies (DEEs). DEEs are characterized by epilepsy and developmental delay in early life.
- Trial name
- NCT04937062
- Testing
- Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Weill Medical College of Cornell University
GNAO1, Epilepsy
Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders.
The goal of this clinical trial is to evaluate the efficacy and safety of the investigational drug ASO-GNAO1 (Tianasen) in pediatric patients with c.607G>A mutation in the GNAO1 gene associated with epilepsy and…
- Conditions
- GNAO1, Epilepsy, Hyperkinesis
- Trial name
- ASO-GNAO1 (NCT07363603)
- Testing
- Antisense oligonucleotide treatment (ASO)
- Where
- Russia
- Volunteers
- 5 people
- Sponsor
- Pirogov Russian National Research Medical University